Anti-TNF-α monoclonal antibody treatment (TNF-α blockers), have been clinically used in the treatment of the aforementioned diseases, which also carry a high risk of atherosclerosis and cardiovascular complications. This evidence concerns the gene TNF and atherosclerosis.